Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG)

Tekgündüz, Emre; Demırkan, Fatih; Vural, Fılız; Göker, Hakan; Özdoğu, Hakan; Kıkı, İlhami; Aydoğdu, İsmet; Kaynar, Leylagül; Erkurt, Mehmet Ali; Cagirgan, Seckin; Beşışık, Sevgi Kalayoğlu; Dağdaş, Simten; Koca, Ebru; Kadıköylü, Gürhan; Gündüz, Eren; Yılmaz, Mehmet; Beköz, Hüseyin Saffet; Ural, Ali Uğur; Baştürk, Abdulkadir; Arat, Mutlu; Albayrak, Murat; Öztürk, Erman; Akyol, Alev; Bolaman, Ali Zahit; Nevruz, Oral; Özkan, Hasan; Ozgur, Gokhan; Altuntaş, Fevzi

doi:10.1016/j.transci.2017.11.010

Cited by 1 publication

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Autologous hematopoietic stem cell transplantation (AHSCT) is often used as a consolidative therapy for patients with newly diagnosed non-Hodgkin lymphoma (NHL) or salvage therapy for those with relapsed or refractory disease (1)(2)(3)(4). The mobilization and collection of adequate CD34 + hematopoietic stem cells (HSCs) is crucial for supporting AHSCT, of which granulocyte colony-stimulating factor (G-CSF) alone or G-CSF plus chemotherapy have been the most common mobilization methods (5)(6)(7)(8). Moreover, plerixafor, a CXCR4 antagonist, has been demonstrated to optimize the mobilization procedures in patients with NHL and multiple myeloma, due to its capability to enhance the HSC mobilization effect of G-CSF (9)(10)(11)(12).…”

Section: Introductionmentioning

confidence: 99%

YF-H-2015005, a CXCR4 Antagonist, for the Mobilization of Hematopoietic Stem Cells in Non-Hodgkin Lymphoma Patients: A Randomized, Controlled, Phase 3 Clinical Trial

Liu

Wang

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Background: YF-H-2015005, a novel CXCR4 antagonist, has been proven to increase the quantities of circulating hematopoietic stem cells (HSCs), which results in an adequate collection of HSCs in non-Hodgkin lymphoma (NHL) patients.Methods: This was a multicenter, double-blind, randomized (1:1), placebo-controlled phase III clinical trial. All patients received granulocyte colony-stimulating factor (G-CSF) for up to 8 consecutive days. YF-H-2015005 or placebo was administrated on the evening of day 4 and continued daily for up to 4 days. Apheresis was conducted 9–10 h after each dose of YF-H-2015005 or placebo. The primary endpoint was the proportion of NHL patients procuring ≥5 × 106/kg CD34+ HSCs within ≤4 apheresis sessions.Results: In total, 101 patients with NHL were enrolled. The proportions of patients achieving primary endpoint were 57 and 12% in YF-H-2015005 and placebo groups, respectively (P < 0.001). Moreover, a higher proportion of YF-H-2015005-treated patients reached a minimum target collection of ≥2 × 106/kg CD34+ HSCs in ≤4 apheresis days compared to placebo-treated patients (86 vs. 38%, P < 0.001). Furthermore, the median time to collect ≥2 or 5 × 106/kg CD34+ HSCs were 1 and 3 days in YF-H-2015005-treated patients, but 4 days and not reached in placebo-treated patients, respectively. No severe treatment emergent adverse events were observed in both YF-H-2015005 treatment and placebo groups.Conclusions: YF-H-2015005 plus G-CSF regimen was a tolerable combination with high efficacy, which might be used to rapidly mobilize and collect HSCs in NHL patients.

show abstract